Adjustable Lens Customizable After Cataract Surgery Is Now Offered at Northwell Health

The latest development in cataract surgery is now available at several Northwell locations including Peconic Bay Medical Center, Syosset Surgical center and Manhattan Eye, Ear, and Throat Hospital. The cutting-edge Light Adjustable Lens (LAL) enables patients and their doctor to design, trial and customize vision after cataract surgery, more often giving patients their very best possible vision without eyeglasses after surgery.

A cataract is a cloudy area in the lens of the eye that leads to a decrease in vision. Cataracts often develop slowly and can affect one or both eyes. Symptoms may include faded colors, blurry or double vision, halos around light, trouble with bright lights, and trouble seeing at night.

“RxSight’s Light Adjustable Lens allows ophthalmologists to give cataract patients even more precise visual outcomes than ever before,” said Richard Braunstein, MD, senior vice president and executive director of ophthalmology at Northwell Health. “We’re always striving to provide the best care possible for our patients, and with this new technology we are living up to that goal.”

The intraocular lens is made of a unique material that reacts to UV light, which is delivered by the Light Delivery Device, as soon as 17 days after surgery. Patients receive three to five light treatments over a period of several weeks, each lasting about 40-150 seconds, depending upon the amount of adjustment needed. The patient must wear special eyeglasses for UV protection from the time of the cataract surgery to the end of the light treatments to protect the new lens from UV light in the environment.

“Small variations in healing happen in most eyes and with the Light Adjustable Lens, we gain the ability to correct even small amounts of nearsightedness, farsightedness and astigmatism,” said Scott Sheren, MD, director of ophthalmology at Northwell Health Eye Institute at Riverhead. “This lens is amazing because you can adjust its shape and thus its power in the eye and this is done without the use of a laser or conventional surgery.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”